Seres therapeutics, nestlÉ health science announce ser-109 co-commercialization license agreement

Cambridge, mass. & lausanne, switzerland--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, announced today that it has entered into an agreement with nestlÉ health science to jointly commercialize ser-109, seres' investigational oral microbiome therapeutic for recurrent clostridioides difficile infection (cdi), in the united states (u.s.) and canada. if approved, ser-109 would become the first-ever fda-approved microbiome therapeutic. under th
mcrb Ratings Summary
mcrb Quant Ranking